About Protein tyrosine phosphatase receptor type C-associated protein
Protein tyrosine phosphatase receptor type C-associated protein (PTPRCAP) is a protein
from Homo sapiens identified by UniProt accession
Q14761, 206 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | Protein tyrosine phosphatase receptor type C-associated protein |
|---|
| UniProt accession | Q14761 |
|---|
| Gene | PTPRCAP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 206 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (36)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.14
- mean reticulocyte volume · score 0.14
- mean corpuscular hemoglobin · score 0.14
- mean corpuscular hemoglobin concentration · score 0.14
- genetic disorder · score 0.12
- Chronic mucocutaneous candidosis · score 0.07
- Abnormality of refraction · score 0.06
- hemoglobin measurement · score 0.05
- sunburn · score 0.05
- immune deficiency, familial variable · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14761-F1 | alphafold | PREDICTED | 57.70 | — |
Amino-acid sequence (206 residues)
MALPCTLGLG MLLALPGALG SGGSAEDSVG SSSVTVVLLL LLLLLLATGL ALAWRRLSRD SGGYYHPARL GAALWGRTRR LLWASPPGRW LQARAELGST DNDLERQEDE QDTDYDHVAD GGLQADPGEG EQQCGEASSP EQVPVRAEEA RDSDTEGDLV LGSPGPASAG GSAEALLSDL HAFAGSAAWD DSARAAGGQG LHVTAL
Explore Protein tyrosine phosphatase receptor type C-associated protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets